The Group's principal activity involves the research, development and commercialization of rational genome engineering technologies. It is a biotech company developing innovative, proprietary technologies for genome engineering. The Company designs protein "scissors" capable of cleaving the Deoxyribonucleic Acid (DNA) at precise sites in living cells. It targets a defective gene and substitutes it by another gene in a precise and controlled manner. The Company's applications are also used for the production of proteins for therapeutic purposes, improvement of seed characteristics and the development of treatments against single-gene disorders. The applications are used in the bioproduction, agronomics, biotherapeutics and research field. The Company operates in France.
Alacra Alerts:
Receive alerts on the latest reports on Cellectis SA
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
